Resources

Explore EPKIN's latest case studies, press releases, publications, and blog posts on AI-driven oncology and immunology research, including the INVOKE trial.
Latest
Case Study
First-in-class Ph1 trial informed by new biology
Ph1 trial of first-in-class drug through identification of new biology; better understanding MoA, biomarker ID and optimized indication selection.
July 21, 2026
Read details

Browse all resources

View all
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Case Study
First-in-class Ph1 trial informed by new biology
Ph1 trial of first-in-class drug through identification of new biology; better understanding MoA, biomarker ID and optimized indication selection.
July 21, 2026
Press Release
Owkin and BeOne Medicines sign clinical supply agreement for Tislelizumab in INVOKE trial of OKN4395
BeOne Medicines will supply tislelizumab, its PD-1 inhibitor, to Owkin's ongoing INVOKE Phase 1a/1b trial of OKN4395 in patients with advanced solid tumors.
July 1, 2026
Blog
Why targeting prostaglandin signalling reawakens the entire antitumor immune response
Clinical validation of the COX2–PGE2/PGD2 axis is moving from epidemiology to mechanism — and reframing how we think about immune-suppressive tumors.
Andy Karabajakian, Maximilien Grandclaudon, Davide Mantiero
June 26, 2026
Blog
INVOKE: Closing the Loop Between AI Prediction and Clinical Validation
The INVOKE study is a global, multicenter, Phase 1a/1b, first-in-human, open-label trial evaluating OKN4395 in patients with advanced solid tumors.
Davide Mantiero, Alistair Jennings
February 19, 2026
Publication
EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression
A first-in-class EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression to restore antitumor immunity.
Maximilien Grandclaudon
et al.
bioRxiv
February 10, 2026
Press Release
Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization.
January 30, 2025
In the Media
How AI helps drug developers skirt pharma’s ‘dirty little secret’
An executive explains how French biotech Owkin used AI in developing its first drug candidate.
STAT News
January 30, 2025
Press Release
Owkin Unveils AI-Driven Oncology & Immunology Pipeline
In-licenses best-in-class asset OKN4395, unveiling Owkin’s AI precision pipeline.
May 23, 2024